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Abstract
Background: Magnesium is essential for numerous physiological functions. Magnesium exists mostly in bone and
the amount is dynamically regulated by skeletal remodeling. Accelerating bone mass loss occurs when magnesium
intake is insufficient; whereas high magnesium could lead to mineralization defects. However, the underlying
magnesium regulatory mechanisms remain elusive. In the present study, we investigated the effects of high
extracellular magnesium concentration on osteogenic differentiation of mesenchymal stromal/stem cells (MSCs)
and the role of magnesium transporter SLC41A1 in the mineralization process.
Methods: Murine MSCs derived from the bone marrow of BALB/c mouse or commercially purchased human MSCs
were treated with osteogenic induction medium containing 5.8 mM magnesium chloride and the osteogenic
differentiation efficiency was compared with that of MSCs in normal differentiation medium containing 0.8 mM
magnesium chloride by cell morphology, gene expression profile of osteogenic markers, and Alizarin Red staining.
Slc41a1 gene knockdown in MSCs was performed by siRNA transfection using Lipofectamine RNAiMAX, and the
differentiation efficiency of siRNA-treated MSCs was also assessed.
Results: High concentration of extracellular magnesium ion inhibited mineralization during osteogenic
differentiation of MSCs. Early osteogenic marker genes including osterix, alkaline phosphatase, and type I collagen
were significantly downregulated in MSCs under high concentration of magnesium, whereas late marker genes
such as osteopontin, osteocalcin, and bone morphogenetic protein 2 were upregulated with statistical significance
compared with those in normal differentiation medium containing 0.8 mM magnesium. siRNA treatment targeting
SLC41A1 magnesium transporter, a member of the solute carrier family with a predominant Mg2+ efflux system,
accelerated the mineralization process and ameliorated the inhibition of mineralization caused by high
concentration of magnesium. High concentration of magnesium significantly upregulated Dkk1 gene expression
and the upregulation was attenuated after the Slc41a1 gene was knocked down. Immunofluorescent staining
showed that Slc41a1 gene knockdown promoted the translocation of phosphorylated β-catenin into nuclei. In
addition, secreted MGP protein was elevated after Slc41a1 was knocked down.
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Conclusions: High concentration of extracellular magnesium modulates gene expression of MSCs during
osteogenic differentiation and inhibits the mineralization process. Additionally, we identified magnesium transporter
SLC41A1 that regulates the interaction of magnesium and MSCs during osteogenic differentiation. Wnt signaling is
suggested to be involved in SLC41A1-mediated regulation. Tissue-specific SLC41A1 could be a potential treatment
for bone mass loss; in addition, caution should be taken regarding the role of magnesium in osteoporosis and the
design of magnesium alloys for implantation.
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Background
Bone tissue is formed by osteoblasts, maintained by os-
teocytes, and broken down by osteoclasts. Physiologic-
ally, bone is constantly remodeled coordinately between
bone resorption by osteoclasts and bone formation by
osteoblasts [1]. Osteoblasts sustain bone mass by secret-
ing proteins which form extracellular matrix that
reinforces the strength of bone after calcium deposition
[2]. Although extracellular calcification in bone cells has
a positive effect for healthy bone, the ectopic calcifica-
tion that occurs in soft tissues may have severe clinical
consequences when localized to organs such as the ar-
teries and kidneys [3]. However, it is still not well known
how cells give rise to minerals and what the underlying
regulatory mechanisms are.
Magnesium, the second most abundant intracellular
free cation and the fourth most abundant metal ion in
the body [4], is known for numerous physiological func-
tions, such as enzymatic activation and Mg–ATP com-
plex formation for energy production [5–7]. Magnesium
has also been shown to inhibit Wnt/β-catenin activity
and reverse calcification of vascular smooth muscle cells
[8]. In many of the cellular functions in which magne-
sium is involved, it acts as a physiological calcium antag-
onist; moreover, both magnesium and calcium play vital
roles in bone metabolism [9, 10], and therefore a balance
between calcium and magnesium is important in bone
physiology [11]. In the human body, magnesium exists
mostly in bone, either on the surface of hydroxyapatite
(HAP), which is a major component of bone and teeth,
or in the hydration shell around the HAP crystal [12].
Because bone serves as the reservoir for magnesium, the
amount of magnesium is regulated dynamically by skel-
etal remodeling during bone resorption and formation
for maintaining proper physiological function [13].
The very limited Mg2+ gradient across the cell mem-
brane indicates that there is a tight regulation for Mg2+
homeostasis [14]. Several magnesium transporters have
so far been identified and suggested to cooperate with
each other for this tight regulation [15], yet few of them
have been investigated at the molecular level. Among
these transporters, solute carrier family 41 member 1
(SLC41A1) has been identified recently as a Na+/Mg2+
exchanger with a predominant Mg2+ efflux system con-
taining the N terminus involved in Mg2+ sensing and
protein kinase activities [16]. SLC41A1 has been linked
with several serious human illnesses such as Parkinson’s
disease, preeclampsia, and nephronophthisis-like pheno-
types. Moreover, SLC41A1 expression is correlated
positively with the level of serum magnesium in head
and neck cancer patients under chemotherapy [17].
Because serum magnesium is associated with bone min-
eral density and calcification, we reason that SLC41A1
may play a role in magnesium regulation for bone me-
tabolism [11, 18]. Additionally, Slc41a1 is upregulated in
some organs when mice are on a low-magnesium-
containing diet [19, 20]. Together with the association
between Slc41a1 expression and the level of serum mag-
nesium in mice during exercise [21], we hypothesize that
SLC41A1 plays a role in magnesium homeostasis during
osteogenic differentiation of MSCs.
Osteoporosis is a progressive disease resulting from an
imbalance between bone deposition and resorption. Ac-
celerating bone mass loss occurs in postmenopause ani-
mals when their magnesium intake is insufficient, and
increased magnesium intake alleviates the osteoporotic
symptoms [22]. On the other hand, high magnesium
concentration leads to mineralization defects possibly
due to magnesium substitution for calcium in the HAP
structure [23]. It is reported that slow release of magne-
sium from scaffolds could contribute to bone regener-
ation in vivo [24, 25]; whereas a hyperphysiological level
of magnesium concentration inhibits extracellular matrix
formation and supports chondrocyte proliferation [26].
Therefore, it is essential to understand the regulatory
mechanisms in which magnesium is involved in the
promotion of mineralization as well as osteoblast gener-
ation. Mesenchymal stromal cells (MSCs) possess prom-
ising potential in clinical application due to their
immunomodulatory effects and the ability to give rise to
various mature progenies, such as osteoblasts, adipo-
cytes, and chondrocytes [27, 28]. In the present study,
we investigate the effect of high extracellular magnesium
concentration on osteogenic differentiation of MSCs and
the role of magnesium transporter SLC41A1 in the
mineralization process during osteogenic differentiation.
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Methods
Cell maintenance and expansion
Mouse bone marrow-derived MSCs (mMSCs) were
obtained from the femoral and tibial bone marrow of a
7–8-week-old male Balb/c mouse purchased from
National Laboratory Animal Center (Taipei, Taiwan) as
described previously [29]. The protocols were approved
by the Taipei Veterans General Hospital Institutional
Animal Care and Use Committee (IACUC 2013-048).
All studies involving animals were in accordance with
appropriate guidelines. The isolated cells were character-
ized by the surface markers using flow cytometry and
assessed by the osteogenic, adipogenic, as well as chon-
drogenic differentiation assays before being further used
for the study. Human MSCs (hMSCs) were purchased
from Cell Applications, Inc. (catalog/lot number 492-
05a/2694; San Diego, CA, USA). This specific population
of MSCs was tested for multilineage differentiation po-
tential before being further used for the study. Cells
from the 12th–15th passages used for the present study
have been confirmed for their stemness prior to the ex-
periments by checking the expression of surface markers
using flow cytometry, and for their hepatogenic, osteo-
genic, as well as adipogenic differentiation potential.
Protocols used for maintenance and expansion of
mMSCs and hMSCs were described previously [30].
Osteogenic differentiation of MSCs
The basal medium used for osteogenic induction was
high-glucose Dulbecco's modified Eagle's medium (HG-
DMEM) for mMSCs and Iscove's modified Dulbecco's
medium (IMDM) for hMSCs supplemented with the in-
duction factors: 0.1 μM dexamethasone (Sigma-Aldrich),
10 mM β-glycerol phosphate (βGP; Sigma-Aldrich), and
0.2 mM ascorbic acid (ASA; Sigma-Aldrich) [31]. The
cells were seeded at 4000 cells/cm2 and were maintained
in culture medium (low-glucose DMEM supplemented
with 10% FBS) for 24 hours before the induction. The
induction medium was changed twice a week.
DMEM and IMDM contain 0.8 mM magnesium ion,
and therefore 0.8 mM magnesium concentration is de-
fined as normal magnesium concentration. The serum
magnesium level in patients with renal disease is around
1 mM [32] and a serum magnesium level around 5 mM is
associated with profound muscle weakness; on the other
hand, physiological magnesium concentrations in soft tis-
sue and bone are 8.5 and 43.2 mmol/kg wet weight re-
spectively [15]. Therefore, for the induction medium with
high concentration of magnesium, DMEM and IMDM
were supplemented with 5 mM MgCl2 (Sigma-Aldrich)
and we defined 5.8 mM MgCl2 as the experimental group
of high magnesium concentration. A 1 M MgCl2 stock
solution was prepared in double-distilled water (ddH2O)
to make the final concentration of magnesium 5.8 mM.
Quantitative real-time polymerase chain reaction
Total RNA was extracted by RNeasy Mini Kit (QIAGEN,
Hilden, Germany) and reverse-transcribed to comple-
mentary DNA by MMLV High Performance Reverse
Transcriptase according to the manufacturer’s instruc-
tions (EPICENTRE, Madison, WI, USA). Quantitative
real-time PCR (qPCR) was performed with TaqMan® Fast
Universal PCR Master Mix (2×) by the Step One plus
real-time PCR system (Applied Biosystems, Foster City,
CA, USA) to determine the relative gene expression pro-
files. Primers used for qPCR are presented in Additional
file 1: Table S1 with ribosomal protein S18 (Rps18) as
the endogenous internal control. Relative mRNA expres-
sion was calculated by the difference of ΔCt (ΔΔCt) of
the target gene from the group without induction (day
0) and under osteogenic induction. The relative value
RQ of gene expression was defined as 2–ΔΔCt.
Alizarin Red S staining and MGP detection
For Alizarin Red staining, after washing in ddH2O three
times formaldehyde-fixed cells were stained with 2% w/v
Alizarin Red S solution (pH 4.1) (Sigma-Aldrich) for
20 minutes, followed by further ddH2O washing twice.
Then 10% cetylpyridinium chloride (CPC; Sigma-
Aldrich) was used to extract the dye by incubating the
stained cells at 37 °C for 20 minutes. The absorbance at
550 nm was measured for quantification.
For qualitative detection of mouse matrix gla protein
(MGP) secreted from mMSCs in condition medium,
mMSCs were cultured in 6-cm culture dishes. Fresh in-
duction medium was added into culture dishes 3 days
before being collected for the assay. MGP assay was per-
formed by MGP ELISA kit according to the manufac-
turer’s instruction (MyBioSource, San Diego, CA, USA)
and the amount of MGP secretion was normalized by
the cell number of the control group.
siRNA transfection
siRNA targeting Slc41a1 was transfected into mMSCs
according to the manufacturer's instructions. Briefly, 50
nM of siRNA against Slc41a1 gene (UCGGAGUCAU-
CAUUGGGUCUCGAAA and UUUCGAGACCCAAU-
GAUGACUCCGA, Slc41a1MSS294789) was transfected
with RNAiMAX transfection reagent (Invitrogen) into
mMSCs for 24 hours at 37 °C. Cells were then washed
with PBS and cultured in osteogenic induction medium
afterward.
Immunofluorescent staining
Primary antibodies against phosphorylated β-catenin
(pSer33/pSer37; Abcam, UK) and phosphorylated p38
MAPK (pThr180/pTyr182; Cell Signaling Technology,
USA) were used at 1:200 dilution according to the
manufacturers’ instructions. Images were taken by Olympus
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FluoView™ FV10i confocal microscope on the same day
using the same settings of laser power and pinhole size.
Statistical analysis
All data for statistical analysis were derived from at least
three independent experiments (indicated as N) and
three technical repeats (indicated as n). Data were
presented as mean ± SEM. Paired Student's t test was
used to compare data from two groups. p < 0.05 was
considered statistically different.
Results
High concentration of extracellular magnesium inhibited
mineralization of mMSCs and hMSCs
To study the effect of extracellular high concentration of
magnesium on mineralization of MSCs during osteo-
genic differentiation, we supplied 5 mM MgCl2 in the
osteogenic induction medium as the experimental group
to make a total 5.8 mM magnesium concentration and
employed Alizarin Red S staining to determine the pres-
ence of calcific deposition. Calcification results from
mineral deposited by the extracellular matrix which is
secreted during maturation of bone cells; therefore it is
an important indicator for osteogenic differentiation.
Our results showed that mMSCs, which were under
osteogenic induction for 12 days, had significantly re-
duced calcium deposition when cultured in the medium
with high magnesium concentration (5.8 mM) compared
with those with physiological magnesium concentration
(0.8 mM) (Fig. 1a). The morphologies of MSCs under
0.8 and 5.8 mM magnesium concentration both turned
flat during osteogenic induction (Fig. 1b). In addition,
there was no significant difference in the cell numbers of
MSCs differentiated under 0.8 and 5.8 mM magnesium
concentration (Fig. 1c).
We further investigated the effects of high extracellu-
lar magnesium on the expression of osteogenic marker
genes of mMSCs. qPCR results showed that high con-
centration of magnesium significantly downregulated the
gene expression of early markers including alkaline
phosphatase (Alpl) on day 3 (p = 0.01) and day 6 (p =
0.016) after induction, osterix (Sp7) on day 6 (p = 0.039),
Fig. 1 High concentration of extracellular magnesium inhibited mineralization of mouse MSCs during osteogenesis. a Alizarin Red S staining
images (left) and quantification (right) of mouse MSCs (mMSCs) 12 days after osteogenic induction with normal (0.8 mM) and high (5.8 mM)
extracellular magnesium concentration. Biological replicate N = 3 and technical replicate n = 3 for every biological replicate. b Images of mMSCs
during osteogenic differentiation with normal and high extracellular magnesium concentration. Scale bar: 100 μm. c Cell number of differentiating
mMSCs under osteogenic induction medium containing 0.8 and 5.8 mM magnesium for 0, 3, 6, and 9 days. Cell number was determined by counting
the DAPI-positive cells (N = 3, n = 7) and normalized by cell number for day 0. Data presented as mean ± SEM (* p < 0.05). D: day
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and alpha-1 type I collagen (Col1a1) on day 6 (p = 0.017)
and day 9 (p = 0.015) after the induction. On the con-
trary, high concentration of magnesium significantly up-
regulated gene expression of late markers including
osteocalcin (Ocn) on day 3 (p < 0.001), day 6 (p = 0.049),
and day 9 (p = 0.001) after induction, osteopontin (Opn)
on day 6 (p = 0.048) and day 9 (p = 0.048) after induc-
tion, and bone morphogenetic protein 2 (Bmp2) on day
9 (p = 0.015) after induction (Fig. 2). Of note, the high
fold increases of ALPL and BMP2 gene expression of
differentiating MSCs compared with those of undiffer-
entiated MSCs may be due to the extremely low
expression of these two genes in undifferentiated cells
(day 0).
Similarly, high magnesium concentration inhibited
mineralization of hMSCs under osteogenic induction for
28 days. qPCR results showed that high concentration of
magnesium significantly downregulated osterix (Sp7)
gene expression on day 14 and upregulated osteonectin
gene expression after day 7. Magnesium had no effect
on gene expression of Runx2 and Col1A1. There is also
no significant difference in cell numbers during osteo-
genic differentiation (more supporting data in Additional
file 2: Figure S1A, S1B, S1C).
Slc41a1 knockdown promoted mineralization and
attenuated magnesium inhibition
In order to identify the potential candidates that modu-
late the interaction of magnesium and MSCs during
osteogenic differentiation, we initially screened several
magnesium transporters, including SLC41A1, SLC41A2
as well as SLC41A3, and found that gene expression of
SLC41A1 in differentiating MSCs was upregulated by
extracellular high magnesium concentration. We hy-
pothesized that SLC41A1 plays a role in magnesium
homeostasis during osteogenic differentiation of MSCs
and therefore silenced Slc41a1 gene expression to study
the effect of Slc41a1 knockdown on mineralization of
MSCs during osteogenic differentiation. Alizarin Red S
staining demonstrated that treatment of siRNA targeting
Slc41a1 promoted calcification of mMSCs. The mMSCs
with Slc41a1 knockdown (KD-MSCs) exhibited calcific
deposition as early as day 6 after osteogenic induction;
whereas there was no calcification of the control group
at the same day (Fig. 3a–c). Promotion of mineralization
was also observed in human MSCs with Slc41a1
knockdown (more supporting data in Additional file 2:
Figure S1E). More interesting, even when cultured in
osteogenic induction medium with high concentration
Fig. 2 High concentration of extracellular magnesium modulated osteogenic differentiation of mMSCs. qPCR results of mMSCs under osteogenic
differentiation for 0, 3, 6, and 9 days (D0, D3, D6, D9) with normal and high extracellular magnesium concentration. Relative gene expression
indicates fold-change of gene expression in comparison with gene expression of undifferentiated MSCs on D0 (N = 3, n = 3), presented as mean
± SEM (* p < 0.05)
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of magnesium, KD-MSCs possessed similar potential for
calcification as KD-MSCs cultured with physiological
magnesium concentration (Fig. 3a–d). High magnesium
concentration did not show significant inhibition on
osteogenic differentiation of KD-MSCs. Regarding the
osteogenic marker genes we tested, the levels of gene ex-
pression were similar between KD-MSCs cultured in
physiological magnesium concentration and KD-MSCs
in high magnesium concentration both 3 and 6 days
after induction (Fig. 3e). Additionally, qPCR results re-
vealed that even before the chemical induction (day 0), KD-
MSCs were likely committed into an osteogenic lineage
compared with wild-type MSCs (more supporting data in
Additional file 2: Figure S2). Because KD-MSCs showed an
extremely high degree of mineralization after 9 days of in-
duction, we did not further perform qPCR assays on day 9.
Fig. 3 Slc41a1 knockdown promoted mineralization and attenuated magnesium inhibition. a Slc41a1 expression of undifferentiated mMSCs after
Slc41a1 gene knockdown (N = 3, n = 3). b, c Alizarin Red S staining (left) and the quantification (right) of wild-type mMSCs (ctrl) and mMSCs with
Slc41a1 gene knockdown (KD) 6 and 12 days after osteogenic induction with normal (N: 0.8 mM) and high (H: 5.8 mM) extracellular magnesium
concentration (N = 3, n = 3). d Images of mMSCs with Slc41a1 gene knockdown before and 3 and 6 days after osteogenic induction with normal
magnesium concentration. Scale bar: 100 μm. e Gene expression of undifferentiated mMSCs with Slc41a1 gene knockdown and 3 and 6 days after
osteogenic induction (D0, D3, D6) under 0.8 and 5.8 mM magnesium concentration. Data normalized by the gene expression of undifferentiated
Slc41a1-knockdown MSCs (D0) and presented as mean ± SEM (N = 3, n = 3) (* p< 0.05)
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Gene expression and secreted MGP were elevated after
Slc41a1 was knocked down
Matrix gla protein (MGP) is known as a developmentally
regulated modulator of mineralization. Our results
showed that gene expression of Mgp increased with
induction time during osteogenesis. Yet there was no
significant difference between the groups cultured in
normal and high magnesium concentration (Fig. 4a, b).
The results demonstrated that magnesium concentration
did not play a major role in regulating Mgp gene expres-
sion. We further investigated the relation of magnesium
concentration and secreted MGP protein level. Even
though gene expression of Mgp was significantly upregu-
lated after Slc41a1 was knocked down in the early stage
of the osteogenic differentiation (Fig. 4c), the results of
ELISA showed that secreted free MGP protein level did
not reflect the mineralization ability between wild-type
and Slc41a1 knockdown groups 6 days after the
induction, indicating that accumulated extracellular
MGP protein was not high enough to affect
mineralization on the 6th day and extracellular MGP
protein was not the cause for the promotion or the in-
hibition of mineralization (Fig. 4d). After 9 days of
osteogenic induction, only wild-type MSCs exhibited
significant differences in secreted MGP level between
normal and high magnesium concentration (p = 0.01).
Because the affinity of MGP to HAP is sensitive to com-
petitive HAP-binding protein and the surrounding ionic
environment, magnesium may act as a competitor
against MGP to reduce MGP–HAP binding and
therefore increase the secreted unbound MGP level.
Meanwhile, extracellular MGP protein secreted from
Slc41a1 KD-MSCs was relatively higher than that from
wild-type MSCs, indicating that MGP protein of KD-
MSCs was not utilized for HAP binding, possibly due to
the matured mineralization of KD-MSCs, and most
MGP was secreted in free form.
SLC41A1 modulated Wnt/β-catenin anti-calcifying
pathway
Magnesium can inhibit Wnt/β-catenin activity and reverse
calcification of vascular smooth muscle cells. Because our
results showed that SLC41A1 mediated the magnesium
regulation of mineralization during MSC osteogenic dif-
ferentiation, we therefore hypothesized that SLC41A1 is
involved in the Wnt/β-catenin anti-calcifying pathway.
qPCR results showed that magnesium concentration did
not have impact on gene expression of Wnt5a of wild-
type MSCs after osteogenic induction, which is in the
early stage of osteogenesis and before the onset of
mineralization. However, high concentration of
magnesium significantly downregulated β-catenin expres-
sion (p = 0.003) and the inhibition was diminished after
the Slc41a1 gene was knocked down. Dickkopf-1 (DKK1)
is one of the secreted antagonists of the Wnt/β-catenin
signaling pathway and its role in inhibiting mineralization
has been well established. Interestingly, high concentra-
tion of magnesium significantly upregulated Dkk1 gene
expression (p = 0.018) and the upregulation was attenu-
ated after Slc41a1 gene knockdown (Fig. 5).
Fig. 4 Slc41a1 knockdown elevated MGP expression. a, b Mgp gene expression of control (ctrl) mMSCs and Slc41a1-knockdown mMSCs (KD) with
normal and high extracellular magnesium concentration before and 3, 6, and 9 days after the osteogenic induction (D0, D3, D6, D9). Data
normalized by the gene expression of undifferentiated ctrl and KD MSCs respectively (D0) (N = 3, n = 3). c Mgp gene expression of control and
Slc41a1 KD-mMSCs with normal extracellular magnesium concentration. Data normalized by Mgp gene expression of undifferentiated control
MSCs (D0) (N = 3, n = 3). d Extracellular secreted MGP concentration obtained by ELISA assay (N = 3, n = 3). MGP matrix gla protein. * p< 0.05
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Results of immunofluorescent staining showed that
phosphorylated β-catenin localized in the nuclei of KD-
MSCs 6 days after the induction; yet such nuclear
localization of phosphorylated β-catenin was not ob-
served in wild-type MSCs during this period of time. In
addition, we also observed that phosphorylated p38 in
KD-MSCs relocated to the cytoplasm from the nuclei on
day 6 after the induction (Fig. 6). The results suggested
that Wnt/β-catenin signaling is involved in SLC41A1-
mediated osteogenic differentiation of MSCs.
Discussion
A recent study showed that the Slc41a1 gene expressed in
mouse blood cells is downregulated immediately after ex-
ercise but returns to the basal level 24 hours after exercise
[21]. The fact that the Mg2+ concentration in blood in-
creases during short-term, high-intensity exercise [33]
highlights the importance of the downregulation of this
specific magnesium transport for maintaining proper
physiological function. The study presented herein is the
first report regarding the roles of SLC41A1 in
mineralization during osteogenic differentiation. We sus-
pect that Wnt signaling is one of SLC41A1-mediated
regulation pathways for MSC osteogenic differentiation
and the underlying mechanisms warrant further investiga-
tion. In addition, microarray data of MSCs in osteogenic
induction medium with physiological magnesium concen-
tration (0.8 mM) for 3 days showed that differentially
expressed genes (DEGs) between wild-type MSCs and
MSCs with Slc41a1 gene knockdown were involved in
focal adhesion and MAPK signaling pathways. Other
DEGs of top-five hits were involved in the protein–protein
interaction network of the podocyte as well as spinal cord
injury (more supporting data in Additional file 2: Figure
S3). The MAPK signaling pathway, focal adhesion, and
Akt-mTOR signaling pathway are known to play roles in
modulating osteogenic differentiation [34–37]. Whether
these pathways are affected by SLC41A1-mediated mag-
nesium ion directly or by SLC41A1-kinase activity will be
investigated in the future.
Fig. 5 Slc41a1 knockdown attenuated the high magnesium-induced inhibition of Wnt signaling. Gene expression of Wnt5a, β-catenin, and Dkk1
in control (ctrl) and Slc41a1 knockdown (KD) mMSCs with normal and high extracellular magnesium concentration before and 3 days after osteo-
genic induction (D0 and D3). Two-way analysis of variance followed by Tukey’s post-hoc tests was performed for multiple comparisons. p < 0.05 is
defined statistically significant; same letters denote no significant differences. Data normalized by the gene expression of undifferentiated wild-
type MSCs (D0) and presented as mean ± SEM (N = 3, n = 3)
Fig. 6 SLC41A1 modulated the localization of phosphorylated β-
catenin. Immunofluorescent staining of phosphorylated β-catenin
(red), phosphorylated p38 mitogen-activated protein kinases (green),
and DAPI (blue) on wild-type (w.t.) MSCs and MSCs treated with
siRNA (si) targeting SLC41A1 magnesium transporter. Staining was
performed before osteogenic induction (day 0), as well as 3 and
6 days after the induction. Scale bar: 50 μm
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Matrix gla protein (MGP) is a developmentally regu-
lated modulator of mineralization. Constitutive MGP ex-
pression in the chick limb has been shown to block
intramembranous and endochondral ossification [38].
Mice lacking MGP die soon after birth due to the
massive calcification of arterial and cartilages [39]. Al-
though it may have other unknown effects on ectopic
calcification, MGP has been suggested as a potent in-
hibitor of HAP crystal growth during mineralization
process [40]. In addition to the competitive role of mag-
nesium against MGP binding HAP crystal, previous
study also demonstrated that high extracellular magne-
sium inhibits excess calcium-induced mineralization and
excess calcium-induced MGP expression in prechondro-
genic cell line ATDC5. Such inhibitions by excess mag-
nesium are suggested to be mediated by inhibiting the
expression of calcium-sensing receptor (CaSR) [41].
Another study also indicated that the inhibition of
mineralization by high concentration of extracellular
Mg2+ may be through the modulation of calcium oscilla-
tions via suppression of spontaneous ATP release and
inactivation of purinergic receptors [42]. Similarly, we
also observed decreased intracellular calcium concentra-
tion as well as decreased calcium influx when mMSCs
were cultured in osteogenic induction medium with high
concentration magnesium after 9 days (more supporting
data in Additional file 2: Figure S4). This phenomenon
could be explained by the competition between calcium
and magnesium ions for the same transporter, such as
transient receptor potential cation channel, subfamily M,
member 7 (TRPM7). TRPM7 is permeable to a number
of divalent metal ions, including Mg2+ and Ca2+; it is
mechanosensitive and important in osteogenesis in
MSCs [43]. The results presented in our study demon-
strated that SLC41A1 is important for the regulation of
magnesium during mineralization; however, we cannot
exclude the roles that TRPM7 and other magnesium/cal-
cium transporters may play during MSC mineralization.
High extracellular magnesium inhibits not only miner-
alized matrix deposition by MSCs [42] and osteoblasts
[44], but also inhibits the excess calcium-promoted
mineralization in prechondrogenic cells [41]. On the
other hand, it has been proposed that deficiency in mag-
nesium causes osteoporosis. Insufficient intake of mag-
nesium reduces the secretion of parathyroid hormone
and vitamin D, and leads to hypocalcaemia as well as the
disturbance of calcium homeostasis [10]. Because para-
thyroid hormone also regulates bone turnover rates and
the homeostasis of the related components, such as cal-
cium and magnesium, it is not surprising that biochem-
ical reactions involved in magnesium and bone
metabolisms are complicated. Some studies showed that
supplement of magnesium in daily diets could alleviate
the rate of bone loss. On the other hand, our study
suggests that caution should be taken when magnesium
supplementation is used as a therapy for bone mass loss
because high magnesium could lead to mineralization
impairment.
Conclusion
High concentration of extracellular magnesium modulates
gene expression of MSCs during osteogenic differentiation
and inhibits the mineralization process. Additionally, we
identified magnesium transporter SLC41A1 that regulates
the interaction of magnesium and MSCs during osteo-
genic differentiation. Knockdown of SLC41A1 promotes
the mineralization during osteogenesis and Wnt signaling
is suggested to be involved in the SLC41A1-mediated
regulation. Together, tissue-specific SLC41A1 could be a
potential treatment for bone mass loss; in addition,
caution should be taken regarding the role of magnesium
in osteoporosis and the design of magnesium alloys for
implantation because local high magnesium concentration
could generate from fast degrading.
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magnesium concentration decreased intracellular calcium concentration of
mouse MSCs 6 days after osteogenic induction. (DOC 1139 kb)
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